Vardenafil (Levitra/Staxyn) Pediatric (Under 12) Dosing

What is the FDA-approved pediatric dose of vardenafil for children under 12?

There is no FDA-approved dose of vardenafil for any child under 12, and there is no approved dose for any patient under 18. The FDA-approved prescribing information for Levitra states explicitly that "safety and effectiveness in pediatric patients have not been established," and no pediatric clinical trials have been registered or completed for this compound in children [1]. Erectile dysfunction, the sole approved indication for vardenafil, does not occur in pre-pubertal children as a primary physiologic condition. Any clinician who receives a request to dose vardenafil in a child under 12 should treat that request as a clinical red flag requiring immediate safeguarding review, not pharmacokinetic calculation.

Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor. It works by blocking the cGMP-specific phosphodiesterase enzyme in smooth muscle, prolonging smooth-muscle relaxation in penile corpus cavernosum tissue after nitric oxide release during sexual stimulation [1]. That physiologic pathway simply does not produce therapeutic benefit in pre-pubertal males, whose reproductive axis has not yet activated the hormonal cascade (gonadotropin-releasing hormone, luteinizing hormone, testosterone) that makes erection and sexual response possible in the adult sense.

No weight-based pediatric dosing formula exists in any published pharmacokinetic study, FDA guidance document, or international formulary. The British National Formulary for Children (BNFc) carries no entry for vardenafil in pediatric patients. The European Medicines Agency has issued no pediatric investigation plan (PIP) that mandates or anticipates a pediatric formulation of vardenafil for children under 18.

Why vardenafil carries no pediatric indication: the pharmacologic and regulatory reasoning

The absence of a pediatric dose is not an oversight. It reflects a deliberate regulatory and clinical conclusion supported by the drug's mechanism, its hemodynamic profile, and the complete absence of a therapeutic need in children.

PDE5 inhibitors and the developing cardiovascular system

Vardenafil produces systemic vasodilation by inhibiting PDE5 in vascular smooth muscle throughout the body, not only in penile tissue. Mean maximum plasma concentration (Cmax) of 18.7 ng/mL is reached in approximately 0.7-0.9 hours after a 10 mg oral dose in healthy adult males, and the drug has a half-life of 4-5 hours [1]. In adults, a mean decrease in supine systolic blood pressure of 7 mmHg and a 8 mmHg drop in diastolic pressure have been recorded at the 10 mg dose compared with placebo [1].

Children's cardiovascular systems are physiologically distinct. Resting heart rate is higher, stroke volume is lower per kilogram than in adults, and baroreceptor reflexes may respond differently to acute vasodilatory load. No pediatric pharmacokinetic modeling has been performed for vardenafil to determine what blood-pressure change a weight-adjusted dose might produce in a 6-year-old or a 10-year-old. Extrapolating adult hemodynamic data to a 20 kg child would be clinically irresponsible.

Hormonal immaturity and the absence of therapeutic target

Erectile function in biologically male individuals is androgen-dependent. Serum testosterone in pre-pubertal boys typically runs below 20 ng/dL. Adult male erectile function requires testosterone in the 300-1000 ng/dL range [2]. Without adequate androgenic priming, the nitric oxide signaling cascade that vardenafil augments is not physiologically active in the way required for the drug to produce any meaningful clinical effect. There is, in short, no disease to treat.

The FDA Pediatric Research Equity Act and vardenafil

The Pediatric Research Equity Act (PREA) requires that sponsors of new drug applications assess safety and effectiveness in pediatric populations when a drug is used in adults for a disease that exists in children [3]. The FDA granted vardenafil a waiver from pediatric studies because erectile dysfunction, as a primary diagnosis, does not occur in children under 18. The FDA's published list of drugs with full waivers from pediatric assessment includes PDE5 inhibitors approved solely for erectile dysfunction.

Off-label PDE5 inhibitor use in pediatric patients: sildenafil, not vardenafil

Some PDE5 inhibitors do have studied pediatric applications, but vardenafil is not among them. Sildenafil (Revatio, not Viagra) is FDA-approved for pediatric pulmonary arterial hypertension (PAH) in patients aged 1-17, using weight-based dosing of 10 mg three times daily for patients weighing <20 kg and 20 mg three times daily for those weighing >20 kg [4]. Tadalafil (Adcirca) is similarly approved for pediatric PAH.

The reason sildenafil gained pediatric approval for PAH and vardenafil did not comes down to sponsor investment in pediatric trials, not pharmacologic superiority. Bayer, the manufacturer of Levitra, never submitted a pediatric indication application for PAH or any other pediatric condition. If a clinician treating a child with PAH or another vascular condition is considering a PDE5 inhibitor, sildenafil (Revatio formulation) and tadalafil (Adcirca formulation) are the only appropriate choices with established pediatric dosing data. Vardenafil should not be substituted.

HealthRX Clinical Decision Framework: PDE5 Inhibitor Selection in Patients Under 18

| Patient scenario | Appropriate PDE5 inhibitor | Appropriate dose | Vardenafil appropriate? | |---|---|---|---| | PAH, weight <20 kg, age 1-17 | Sildenafil (Revatio) | 10 mg TID | No | | PAH, weight >20 kg, age 1-17 | Sildenafil (Revatio) | 20 mg TID | No | | PAH, age 1-17, tadalafil preferred | Tadalafil (Adcirca) | 40 mg once daily | No | | Erectile dysfunction, age <18 | None approved | None approved | No | | Erectile dysfunction, age 18+ | Vardenafil, sildenafil, tadalafil, avanafil | Per adult PI | Adult patients only |

Clinical considerations if vardenafil exposure occurs in a child under 12

Accidental ingestion is the most likely scenario in which a child under 12 would be exposed to vardenafil. A parent or caregiver's prescription tablet may be accessed by a toddler or young child. Poison Control guidance should be sought immediately at 1-800-222-1222.

The primary acute concern after vardenafil ingestion in a child is symptomatic hypotension. The drug's vasodilatory action is dose-dependent. A 10 mg adult tablet could represent a very large weight-adjusted dose in a small child. Signs to monitor include dizziness, flushing, tachycardia, hypotension, and, less commonly, priapism (prolonged erection lasting more than 4 hours, which constitutes a urologic emergency at any age). Transient visual disturbances, including changes in color vision related to PDE6 inhibition in retinal cells, have been reported in adult clinical trials [1].

Management of acute vardenafil ingestion in a pediatric patient follows general poisoning protocols: supportive care, IV fluid resuscitation for symptomatic hypotension, and cardiac monitoring. Alpha-adrenergic agonists such as phenylephrine may be considered for severe hypotension refractory to fluids, though experience in children is limited to case reports. No specific reversal agent exists.

Priapism occurring in a child after PDE5 inhibitor ingestion requires emergent urology consultation. The standard adult protocol of intracorporeal phenylephrine injection (100-200 mcg, may repeat every 3-5 minutes for up to 1 hour) is adapted by pediatric urologists based on body weight, but this falls entirely outside routine prescribing and into acute emergency management [5].

What prescribers must document when declining to prescribe vardenafil to a pediatric patient

If a request reaches a prescriber to write vardenafil for a patient under 18, the prescriber's chart note should clearly record:

1. The patient's age and the absence of any FDA-approved indication for this drug in patients under 18.
2. The absence of published weight-based dosing in any regulatory document, pharmacokinetic study, or established formulary.
3. The clinical reasoning for declining, including the cardiovascular hemodynamic risk in a child with no established therapeutic benefit.
4. Any referral made, such as to a pediatric urologist, pediatric cardiologist, or child and adolescent psychiatry if the request reflects a concerning context.
5. Whether a mandatory reporting obligation (such as to child protective services) was assessed based on the clinical context of the request.

The American Academy of Pediatrics recommends that clinicians document the reasoning behind off-label decisions, and declining an off-label prescription carries the same documentation obligation as writing one [6].

Adult dosing of vardenafil: the approved context for reference

Understanding why adult dosing exists helps clarify why no pediatric analog is scientifically grounded.

In adult men with erectile dysfunction, the approved starting dose of vardenafil (Levitra) is 10 mg taken orally 30-60 minutes before sexual activity, with a maximum frequency of once per day [1]. The dose may be adjusted to 5 mg or 20 mg based on tolerability and response. For the orally disintegrating tablet formulation (Staxyn), the dose is fixed at 10 mg and cannot be adjusted, which is why the orally disintegrating form is not considered interchangeable with the film-coated tablet on a milligram-per-milligram basis [1].

Renal impairment does not require dose adjustment. Hepatic impairment (Child-Pugh B) calls for a starting dose of 5 mg, with a maximum of 10 mg. Patients over 65 years old begin at 5 mg. The drug is contraindicated with nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) due to the risk of severe hypotension [1].

Porst et al. conducted a randomized, double-blind, placebo-controlled trial (N=439) in men with erectile dysfunction associated with type 1 or type 2 diabetes, demonstrating statistically significant improvement in erectile function domain scores at both 10 mg and 20 mg doses compared with placebo (P<0.001), with a favorable safety profile in that population [7]. That trial, published in the International Journal of Impotence Research in 2003, remains one of the cited evidence bases for vardenafil efficacy in adult men with comorbid diabetes. All enrolled participants were adults. No pediatric data existed then or exist now.

The Endocrine Society's 2018 clinical practice guideline on male sexual dysfunction recommends PDE5 inhibitors as first-line pharmacotherapy for erectile dysfunction in adult men with confirmed diagnosis, and specifies adult patient populations throughout [8]. No pediatric exemption or exploratory recommendation appears in that guideline.

Reporting accidental pediatric exposure or inappropriate prescribing

If a child under 12 has been given or has accidentally taken vardenafil, multiple reporting channels are appropriate:

• Poison Control Network: 1-800-222-1222 (U.S.) for immediate toxicologic guidance.
• FDA MedWatch: Online at fda.gov/safety/medwatch or 1-800-FDA-1088, to report adverse events including pediatric accidental ingestion.
• State child protective services: If the exposure context suggests abuse or neglect, a mandated reporting obligation may apply.
• Institutional pharmacy review: If the drug was dispensed to a child through any prescribing pathway, a pharmacovigilance review should be triggered.

The FDA's Adverse Event Reporting System (FAERS) database accepts voluntary reports from clinicians and consumers. These reports contribute to post-marketing surveillance that could eventually alter labeling if a pattern emerged. Reporting is not optional for healthcare professionals who become aware of a serious adverse event in a pediatric patient [9].

Storage, access prevention, and caregiver education

Adults who are prescribed vardenafil and live with children should receive specific counseling on medication storage. The FDA's "Up and Away" campaign recommends storing all medications in a location that is both out of sight and out of reach of children, in a locked cabinet if possible [10].

Vardenafil tablets are small, often film-coated, and can appear similar to candy to a young child. The 10 mg tablet is the standard dose; even one tablet represents a potentially dangerous hemodynamic load for a child under 12. Caregivers should be reminded that child-resistant caps are not childproof. A child who is motivated can open many pharmaceutical bottles given enough time. Locked pill organizers and locked medicine cabinets provide substantially better protection.

Staxyn (orally disintegrating tablet) dissolves rapidly on contact with saliva, which means accidental ingestion in a young child may not be immediately obvious. Caregivers should store Staxyn in its original blister packaging inside a locked location, not loose in a purse or nightstand drawer.